Celgene News

Titan International : "We had management on the show... they were optimistic. I share their optimism.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.

Since my last article in February about Myrexis we have seen a small pop in the share price and a subsequent drop as well.

Here's a look at some featured job openings in or around the Summit community: Fixed Income Sales , R. Seelaus & Co., Inc.

The administering of clinical trials in the biopharmaceutical industry can be an extremely lengthy, pricey, and resource-intensive process for the organizations participating, especially for the smaller start-up firms.

's stock had its "neutral" rating reiterated by Zacks in a note issued to investors on Friday.

New England Journal of Medicine Reports on Three Phase III Revlimid Trials in Patients With Newly Diagnosed Multiple Myeloma Consistent progression-free survival improvement shown with continuous lenalidomide therapy in elderly patients not eligible for transplant and as maintenance therapy in patients following autologous stem cell transplant ... (more)

Apple Inc. : Jim Cramer ranked this stock a Buy . The stock closed at $569.18, its 52-week high is $644.00, and its 52-week low is $310.50. Allergan Inc.

This weekend, Jackie Fouse will pick up her doctorate in finance, almost a decade after starting the program.

Money Manager Bryan Perry, author of Cash Machine , will appear on "Tim Connolly's Winning Strategies" on Friday, May 11 at 12:00 p.m. CT.

A 60% jump in Vertex this week has investors a bit jealous given the market's pre-summer swoon.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia The Food and Drug Administration said certain patients treated with Celgene Corp.'s cancer drug Revlimid have an increased risk of developing some new types of cancers.

In this position, he will be responsible for global legal strategy at Celgene and will serve on the company's Management Committee.

Tuesday, May 8, 2012 Celgene will present at the Baird 2012 Growth Stock Conference at 12:20 p.m. ET.

Are these declines worth buying or declines that have to be avoided? That's the biggest question I've seen during this earnings period, and it was on display big-time Friday.

HMS Holdings Corp. : After HMS Holdings reported weaker than expected Q1 results and lowered its 2012 guidance, Oppenheimer thinks that the headwinds facing the company are transitory.

Celgene's latest earnings release fits into this category well. Although the company missed on several product fronts in the first quarter, they stated that there was positive momentum heading into the second quarter.